All three drugs displayed lower toxicities against CD34+ HSPCs, shown by a minimal loss of CD34+ cells and expansion of differentiated CD15+ myeloid cells, than against AML cells (CD34+ LC50 for AML 8227 and cord blood: Budesonide = 4.04 nM, and 69.95 nM; Mometasone = 0.86 nM and 50.76 nM and Halcinonide = 3.81 nM and 68.28 nM, Fig. 6e). The gene discussed is CD34; the disease is acute myeloid leukemia.